Chemotherapy-induced Nausea and Vomiting Clinical Trial
— ACTINOfficial title:
Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail
This is a randomized, controlled cross-over trial. The hypothesis of this study is that the differences in manual acupuncture manipulation can impact clinical effect though the acupuncturists follow the same needling regimen. In this study, acupuncturist 1 (clinical experience >15 years) and acupuncturist 2 (<5 years) will give treatments to cancer patients receiving cisplatin chemotherapy (n=36) for at least two continuous cycles, once per day, 5 days per cycle. Acupuncturist 1 determines all the treatment regimens (selection of acupoints and methods of needling manipulation, needle retention time). Randomly, half of the patients will receive treatments from acupuncturist 1 in the first treatment cycle and from acupuncturist 2 in the second cycle; while the other half will be treated in other way round. There is a washout period (21 days) between two cycles. The needling manipulation of two acupuncturists will be measured objectively during treatments. The clinical effect will be measured by the control of vomiting and nausea during and after chemotherapy treatments.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Confirmed diagnosis of cancer - Must receive cancer chemotherapy containing cisplatin - Able to complete at least two continuous chemotherapy treatment cycles - Karnofsky performance status grade =60 - Must use 5-TH receptor antagonists as an antiemetic drug in the chemotherapy duration Exclusion Criteria: - Concurrent neoplasms or illness that induces nausea independent of chemotherapy - Receiving radiotherapy - Received acupuncture treatments for other conditions less than 4 weeks before chemotherapy treatment - Severe infection - Severe heart, liver, kidney and brain diseases - Unconsciousness - Psychosis - Language barriers - Cardiac pacemaker - Radiotherapy or hormone therapy during chemotherapy treatments |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Xiyuan Hospital, China Academy of Chinese Medical Sciences | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing University of Chinese Medicine | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | patient communication satisfaction scale | day 5 on each study period | No | |
Other | Acupuncture related adverse events | faintng during acupuncture treatment, sticking of needle, bleeding in the needling hole, broken needles | day 1-5 each study period | Yes |
Other | Adverse events (not acupuncture treatment specified) | day 1-5 each study period | Yes | |
Other | Needling manipulation parameters | Displacement Frequency (Hz) Displacement Amplitude (pk-pk) Rotation Frequency (Hz) Rotation Amplitude (pk-pk) | day 1-5 each study period | No |
Primary | NCI nausea and vomiting rating scale | day1-8 on each study period | No | |
Secondary | Rhodes Scale | day1-5 on each study period | No | |
Secondary | global assessment on effectiveness by patients (VAS) | day 5 on each study period | No | |
Secondary | patients' confidence towards acupuncture treatment(VAS) | day 1,5 on each study period | No | |
Secondary | global satisfaction for acupuncture treatments | day 5 on each study period | No | |
Secondary | Acupuncture Expectancy Scale (AES) | day 1, 3, 5 on each study period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04054193 -
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
|
Phase 4 | |
Recruiting |
NCT04430361 -
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
|
Phase 2 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Completed |
NCT02285647 -
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
|
Phase 1 | |
Terminated |
NCT01874119 -
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT01757210 -
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
|
N/A | |
Completed |
NCT01442376 -
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
|
Phase 3 | |
Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
Terminated |
NCT02519842 -
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
|
Phase 3 | |
Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
Completed |
NCT02909478 -
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
|
Phase 3 | |
Terminated |
NCT03237611 -
Low Dose Aprepitant for Patients Receiving Carboplatin
|
Phase 2 | |
Completed |
NCT03649230 -
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
|
||
Not yet recruiting |
NCT02933099 -
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 3 | |
Completed |
NCT02557035 -
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
|
Phase 3 | |
Completed |
NCT00787566 -
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT06121414 -
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
|
N/A | |
Completed |
NCT04918069 -
Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)
|
Phase 2 | |
Completed |
NCT05851625 -
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
|
N/A |